CN101584732A - The pharmaceutical composition that is used for blood fat reducing - Google Patents
The pharmaceutical composition that is used for blood fat reducing Download PDFInfo
- Publication number
- CN101584732A CN101584732A CNA2009100804986A CN200910080498A CN101584732A CN 101584732 A CN101584732 A CN 101584732A CN A2009100804986 A CNA2009100804986 A CN A2009100804986A CN 200910080498 A CN200910080498 A CN 200910080498A CN 101584732 A CN101584732 A CN 101584732A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- calcium
- magnesium
- chromium
- zinc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 31
- 210000004369 blood Anatomy 0.000 title claims abstract description 31
- 230000001603 reducing effect Effects 0.000 title claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 68
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 68
- 239000011720 vitamin B Substances 0.000 claims abstract description 68
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 60
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 56
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 53
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 45
- 239000011651 chromium Substances 0.000 claims abstract description 41
- 235000012721 chromium Nutrition 0.000 claims abstract description 39
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 38
- 239000011777 magnesium Substances 0.000 claims abstract description 38
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 37
- 239000011575 calcium Substances 0.000 claims abstract description 36
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 35
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 35
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 35
- 235000001465 calcium Nutrition 0.000 claims abstract description 35
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 31
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 31
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 31
- 239000011710 vitamin D Substances 0.000 claims abstract description 31
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 31
- 229940046008 vitamin d Drugs 0.000 claims abstract description 31
- 239000011701 zinc Substances 0.000 claims abstract description 30
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 30
- 235000016804 zinc Nutrition 0.000 claims abstract description 30
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 29
- 239000011669 selenium Substances 0.000 claims abstract description 29
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 29
- 239000011718 vitamin C Substances 0.000 claims abstract description 29
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 28
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 28
- 229940046009 vitamin E Drugs 0.000 claims abstract description 28
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 28
- 239000011709 vitamin E Substances 0.000 claims abstract description 28
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000011733 molybdenum Substances 0.000 claims abstract description 27
- 229910052750 molybdenum Inorganic materials 0.000 claims abstract description 27
- 235000016768 molybdenum Nutrition 0.000 claims abstract description 27
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 25
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 25
- 239000011719 vitamin A Substances 0.000 claims abstract description 25
- 229940045997 vitamin a Drugs 0.000 claims abstract description 25
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 23
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 23
- 239000011648 beta-carotene Substances 0.000 claims abstract description 23
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 23
- 229960002747 betacarotene Drugs 0.000 claims abstract description 23
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 23
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000011649 selenium Nutrition 0.000 claims abstract description 19
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 43
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 42
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 37
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 21
- 229960002685 biotin Drugs 0.000 claims description 21
- 235000020958 biotin Nutrition 0.000 claims description 21
- 239000011616 biotin Substances 0.000 claims description 21
- 229940055726 pantothenic acid Drugs 0.000 claims description 21
- 235000019161 pantothenic acid Nutrition 0.000 claims description 21
- 239000011713 pantothenic acid Substances 0.000 claims description 21
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 18
- 229960000304 folic acid Drugs 0.000 claims description 18
- 235000019152 folic acid Nutrition 0.000 claims description 18
- 239000011724 folic acid Substances 0.000 claims description 18
- 229960003471 retinol Drugs 0.000 claims description 10
- 235000020944 retinol Nutrition 0.000 claims description 10
- 239000011607 retinol Substances 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 8
- 235000013619 trace mineral Nutrition 0.000 abstract description 36
- 239000011573 trace mineral Substances 0.000 abstract description 36
- 239000000203 mixture Substances 0.000 abstract description 25
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 42
- 229940091250 magnesium supplement Drugs 0.000 description 30
- 229960005069 calcium Drugs 0.000 description 28
- 239000003925 fat Substances 0.000 description 22
- 229940091258 selenium supplement Drugs 0.000 description 21
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 19
- 230000006870 function Effects 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 11
- -1 nicotiamide Chemical compound 0.000 description 11
- 239000000654 additive Substances 0.000 description 10
- 229940087168 alpha tocopherol Drugs 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 229960000984 tocofersolan Drugs 0.000 description 10
- 239000002076 α-tocopherol Substances 0.000 description 10
- 235000004835 α-tocopherol Nutrition 0.000 description 10
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000000996 additive effect Effects 0.000 description 9
- 229940107218 chromium Drugs 0.000 description 9
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- 230000004060 metabolic process Effects 0.000 description 9
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 8
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 8
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 description 8
- 239000000626 magnesium lactate Substances 0.000 description 8
- 235000015229 magnesium lactate Nutrition 0.000 description 8
- 229960004658 magnesium lactate Drugs 0.000 description 8
- 239000011655 sodium selenate Substances 0.000 description 8
- 235000018716 sodium selenate Nutrition 0.000 description 8
- 229960001881 sodium selenate Drugs 0.000 description 8
- 239000011576 zinc lactate Substances 0.000 description 8
- 235000000193 zinc lactate Nutrition 0.000 description 8
- 229940050168 zinc lactate Drugs 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 229910000323 aluminium silicate Inorganic materials 0.000 description 7
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 7
- 239000001527 calcium lactate Substances 0.000 description 7
- 235000011086 calcium lactate Nutrition 0.000 description 7
- 229960002401 calcium lactate Drugs 0.000 description 7
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000011684 sodium molybdate Substances 0.000 description 6
- 235000015393 sodium molybdate Nutrition 0.000 description 6
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229940089653 folic acid 0.3 mg Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000007698 birth defect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229940046374 chromium picolinate Drugs 0.000 description 2
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 239000000745 gonadal hormone Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- VLAPMBHFAWRUQP-UHFFFAOYSA-L molybdic acid Chemical compound O[Mo](O)(=O)=O VLAPMBHFAWRUQP-UHFFFAOYSA-L 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 208000005368 osteomalacia Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102000003670 Carboxypeptidase B Human genes 0.000 description 1
- 108090000087 Carboxypeptidase B Proteins 0.000 description 1
- 229910021556 Chromium(III) chloride Inorganic materials 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- JJWSNOOGIUMOEE-UHFFFAOYSA-N Monomethylmercury Chemical compound [Hg]C JJWSNOOGIUMOEE-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- XSCQURIRMINZIY-UHFFFAOYSA-N [Se].COC(C1=CC=CC=C1)OC#N Chemical compound [Se].COC(C1=CC=CC=C1)OC#N XSCQURIRMINZIY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000170 anti-cariogenic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011805 ball Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001362 calcium malate Substances 0.000 description 1
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 description 1
- 229940016114 calcium malate Drugs 0.000 description 1
- 235000011038 calcium malates Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- UCTLRSWJYQTBFZ-DDPQNLDTSA-N cholesta-5,7-dien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC=C21 UCTLRSWJYQTBFZ-DDPQNLDTSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960000359 chromic chloride Drugs 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- HPCCGRCEBFBZQP-UHFFFAOYSA-N chromium;pyridine-3-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CN=C1 HPCCGRCEBFBZQP-UHFFFAOYSA-N 0.000 description 1
- 150000004777 chromones Chemical class 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- UBFWAFZODRGFIF-UHFFFAOYSA-N cyanic acid;selenium Chemical compound [Se].OC#N UBFWAFZODRGFIF-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000036654 deficiency anemia Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 description 1
- 229910000395 dimagnesium phosphate Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940063755 folic acid 0.1 mg Drugs 0.000 description 1
- 229940083563 folic acid 1 mg Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 239000011742 magnesium glycerophosphate Substances 0.000 description 1
- 235000001130 magnesium glycerophosphate Nutrition 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- BHJKUVVFSKEBEX-UHFFFAOYSA-L magnesium;2,3-dihydroxypropyl phosphate Chemical compound [Mg+2].OCC(O)COP([O-])([O-])=O BHJKUVVFSKEBEX-UHFFFAOYSA-L 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229940089807 pantothenic acid 5 mg Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 235000013904 zinc acetate Nutrition 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 229940043825 zinc carbonate Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 229940110280 zinc methionine Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- CNMFGFBWPBBGKX-SCGRZTRASA-L zinc;(2s)-2-amino-4-methylsulfanylbutanoate Chemical compound [Zn+2].CSCC[C@H](N)C([O-])=O.CSCC[C@H](N)C([O-])=O CNMFGFBWPBBGKX-SCGRZTRASA-L 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A kind of pharmaceutical composition that is used for blood fat reducing, said composition comprises Herb Gynostemmae Pentaphylli, vitamin A, beta-carotene, compound vitamin B, vitamin C, vitamin D, vitamin E and macroelement calcium, magnesium and trace element zinc, selenium, chromium, molybdenum, mainly be applicable to people with hyperlipidemia, very effective aspect blood fat reducing, but chronic administration or use by the course of treatment.
Description
Technical field:
The present invention relates to the Medicines and Health Product technical field; Pharmaceutical composition in particular for blood fat reducing.
Background technology:
Said composition comprises Herb Gynostemmae Pentaphylli, vitamin A, beta-carotene, compound vitamin B, vitamin C, vitamin D, vitamin E and macroelement calcium, magnesium and trace element zinc, selenium, chromium, molybdenum.
Herb Gynostemmae Pentaphylli is a kind ofly can air making-up and spleen enlivening be arranged as the natural Chinese medicine of health food, removing heat from the lung and dissipating phlegm, the effect of tranquilizing by nourishing the heart; Clinical be used for the treatment of insufficiency of the spleen weak, gas Tianjin two void, lung-heat expectorant is thick, cough is panted, palpitation and insomnia, diseases such as emission due to deficiency of the kidney; Modern pharmacological research confirms that Herb Gynostemmae Pentaphylli has: 1, delaying senility function, and Herb Gynostemmae Pentaphylli and total saponins thereof can prolong biological cell and fruit bat, the life-span of mice, obvious SOD activity improving, the content of lipofuscin in the reduction heart, brain, the hepatocyte; 2, effect for reducing blood fat; 3, enhance immunity effect, Herb Gynostemmae Pentaphylli and total saponins thereof can significantly increase nonspecific immunity, cellular immunization, humoral immune function; 4, strong body anti-stress effect, Herb Gynostemmae Pentaphylli and total saponins thereof can obviously improve weak sign, have effects such as resisting fatigue, anti-hypoxia, high temperature resistance, anti-low temperature; 5, influence the organism metabolism effect, Herb Gynostemmae Pentaphylli and total saponins thereof have obvious blood lipid-reducing blood sugar-decreasing effect, can also improve the protein synthesis of spleen, testis, brain and blood; 6, antitumor action; The effect of 7, calmness, hypnosis, analgesia and enhancing learning and memory; 8, increase coronary flow, resist myocardial ischemia, the cerebral blood flow increasing amount, suppress effect such as thrombosis; 9, have concurrently male to laboratory animal and the effect of estrogen sample; 10, promote laboratory animal liver cell regeneration effect; 11, also have effects such as antibacterium, antifungal, antiinflammatory, inhibition calculus, black hair, hair care, beauty treatment in addition.
Vitamin A also claims retinol, the effect that improves vision, prevents nyctalopia is arranged, participate in glycogen and proteinic synthetic, can promote mucopolysaccharide synthetic, influence renewal, the growth of osseous tissue, long bone is grown to both-end, beta-carotene can change vitamin A under the effect of enzyme in vivo, the effect of performance vitamin A, beta-carotene has the effect that suppresses LDL cholesterol oxidation reaction with vitamin E, vitamin C in the mode of cooperative compensating.
Vitamin B group participates in body internal protein, fat and sugar metabolism, makes the excitement of brain cell and inhibition be in poised state, and it comprises vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid etc., collaborative in vivo performance physiological action.Vitamin B
1Participate in body internal protein, fat, breakdown of carbohydrates metabolism and anabolism, can show vitamin B1 deficiency during shortage is the various dysbolismus of representative, vitamin B in addition
1Also participate in the neural impulse reaction, keep myocardium normal function, keep normal appetite, gastrointestinal peristalsis and digestive juice secretion etc.; Vitamin B
2Have another name called riboflavin, it is the ingredient of many important coenzyme in the body, participate in intravital substance metabolism, guarantee that vivo oxidation reduction reaction and energy generate, participate in anti-oxidative defense system in the body, mainly show oral cavity reproductive system syndrome, retardation of growth, iron deficiency anemia, moisture dermatitis, minimizing erythropoiesis, the systemic-function that affects the nerves, the vision etc. that reduces during shortage; Nicotiamide claims niacin amide or vitamin PP again, and its physiological function is to participate in the body intracellular metabolic, keeps normal neurological function, and pellagra can take place during shortage in synthesizing of assurance gonadal hormone etc., mainly shows as dermatitis, diarrhoea, dull-witted three big symptoms; Pantothenic acid extensively exists in each organism, participates in metabolic activity widely, and known have 70 plurality of enzymes all to need pantothenic acid to participate in all kinds of biochemical reaction of catalysis body, otherwise just can Metabolic disorder; Biotin also is a kind of vitamin B group, coordinates to participate in the metabolism of human body matter and energy with other vitamin B group, and it is synthetic with nucleic acid, and the compositive relation of gonadal hormone is close, and it also has control poliosis, bareheaded effect; Vitamin B
6Play the coenzyme effect of transaminase, amino acid decarboxylases in vivo, guarantee the metabolism of materials such as aminoacid, glycogen, fatty acid and one carbon unit, nicotinic acid, guarantee the normal propagation of nucleic acid and proteinic synthetic and cell, guarantee homergy with neurotransmitteies such as a hydroxytryptamine, taurine, dopamine, guarantee normal immunologic function, immunity degradation during shortage also can cause neural infringement; Vitamin B
12Participate in nucleic acid in vivo, choline, amino acid whose synthetic and fat and sugared metabolism, to hemopoietic function of bone marrow, the gastrointestinal epithelial cells function, liver function and nervous system myelin functional integrity have certain effect, it is the necessary vitamin of intelligence of bringing into normal play, not only cause dysnoesia if lack, also nutritional anemia can occur, influence is to blood supply in the brain; Folic acid participates in the synthetic of aminoacid and nucleic acid, and and vitamin B
12The common generation that promotes cell is with ripe, and normal cell can not carry out mitosis during shortage, the neurological symptom can occur, as: the loss of memory, depression and dementia etc.;
Vitamin C claims ascorbic acid again, vitamin C and collagen in close relations, the vessel softening effect is not only arranged, and the effect that purifies the blood in addition prevents arteriosclerosis, in cholesterol metabolism, play an important role, can effectively reduce neutral fat, can also promote the absorption of human body, for hemopoietic provides essential raw material ferrum in the food, simultaneously, vitamin C regain one's strength, aspect effect such as allaying tiredness, keeping tensions down emotion is obvious;
Vitamin D is the sterols derivant, and the subcutaneous dehydrocholesterol of human body produces vitamin D through ultraviolet radiation
3, ergosterol produces vitamin D behind ultraviolet radiation
2, the two originates different, the function unanimity, and the importance of vitamin D is to regulate the metabolism of calcium and phosphorus in human nutrition; Vitamin D promotes calcium in little intestinal absorption, the then a large amount of calcium of the D that is deficient in vitamin are discharged by feces, thereby cause the human body calcium deficiency, and rickets can take place the child, become the calcium phosphorus of storing in the human body to exhaust and can cause osteomalacia, modal osteomalacia crowd is anemia of pregnant woman, wet nurse and old people.
Vitamin E is all general designations with the bioactive chromone derivative of alpha-tocopherol, and wherein the activity of alpha-tocopherol is the highest, has antioxidation, avoids the effect of biomembrane generation lipid peroxidation; Stop the effect of LDL oxidation formation, thereby prevent the generation of atherosclerosis and cardiovascular disease; Also have to regulate immunity, slow down aging, inhibition tumor in addition, promote fetal development and reproductive performance to reach the protective effect of nerve and skeleton etc.
Calcium is the macroelement that body weight for humans is wanted, main two aspects that play a part, the one, constitute sclerous tissueses such as bone tooth, the 2nd, with protein bound or constitute the material of specific function with the form of calcium ion, form in so-called miscible calcium pool and the bone tooth calcium and keep dynamic equilibrium, all cells all need its normal function of calcium competence exertion in the body; Calcium deficiency can cause that also endocrine dysfunction and cell cycle regulation are malfunctioning.
Magnesium topmost function in human body is the generation of containment free radical, and free radical is short old and feeble factor, also is the factor that mainly causes birth defect; Another function of magnesium is to bring into play the effect of protection skeleton with calcium and vitamin D, and osteoporosis takes place magnesium deficiency easily, fractures easily; Magnesium is protected heart in addition and is prevented and treated the function etc. of diabetes in addition.
Trace element zinc is merged in the biomacromolecule ligand---in protein, nucleic acid, the film (being mainly memebrane protein), generate stable metallic biomacromolecule complex---metalloprotein, metalloproteinase nucleic acid complex etc., at present, known these materials participate in the synthetic and degradation process of carbohydrate, lipid, protein and nucleic acid, and the existence of zinc enzyme is all arranged in six big fermentoids; Zinc also is the essential element of enhance immunity vigor; Zinc can promote that proinsulin is converted into insulin by activating protaminase, and zinc deficiency makes insulin be obstructed in the activity of peripheral tissues, and it is unusual to cause glucose tolerance curve.
Trace element-selenium has obvious reduction serum total cholesterol, triglyceride and lipid peroxide, improves high density lipoprotein, the metabolic effect of superabundant fats in the acceleration bodies; Selenium also has the strong anti-oxidation function, and the protection embryo is not subjected to the injury of superoxides, prevention of cardiac; Anticancer by enhance immunity recognition system removing cancerous cell; Remove and the drainage heavy metal ion, hydrargyrum, methyl mercury, cadmium, lead etc. are had Detoxication, and heavy metal pollution is mainly to cause the birth defect factor; Scarce selenium can make the human insulin secretion reduce, impaired glucose tolerance, and oxidation resistance descends and quickens human senility and intelligence decline.
Chromium is insulin " collaborative hormone ", to have the effect of active organochromium compounds " glucose tolerance factor (GTF) " form enhancing insulin, mainly be to keep normal carbohydrate metabolism of body and lipid metabolism, following symptom can occur when not enough: weaken glucose tolerance, increase the weight of hyperglycemia, glucose in urine, hypoglycemia, the circulation of acceleration insulin, reduce Insulin receptor INSR quantity, reduce the insulin binding ability, lose weight, increase fat content, increase vision pressure etc.The chromium of two kinds of valence states of stable existence in the environment, i.e. trivalent chromium and Cr VI, trivalent chromium has physiologically active, uses useful and harmlessly in an amount of scope, and Cr VI is a kind of strong oxidizer, and human body is had toxic and side effects.
Molybdenum is one of micro elements needed by human, it is the formation element of plurality of enzymes, participate in the utilization of ferrum, promote erythrocytic growth and maturation, can prevent anemia, and can help the metabolism of carbohydrate and fat, it participates in removing the murder by poisoning of poisonous aldehydes in the human body, eliminate human free radical, have anticancer, defying age, enhancing immunity and anticariogenic function; Scarce molybdenum can bring out cardiovascular disease, cancer and dental caries.
Application contains Herb Gynostemmae Pentaphylli, vitamin A, beta-carotene, vitamin B
1, vitamin B
2, vitamin B
6, nicotiamide, pantothenic acid, biotin, vitamin B
12, folic acid, vitamin C, vitamin D, vitamin E and macroelement calcium, magnesium and trace element zinc, selenium, chromium, molybdenum be known as the compositions of active component, but with Herb Gynostemmae Pentaphylli, vitamin A, beta-carotene, vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid, vitamin C, vitamin D, vitamin E and macroelement calcium, magnesium and trace element zinc, selenium, chromium, the molybdenum compatibility pharmaceutical composition report as yet that is used for blood fat reducing.
Current medicine that is used for blood fat reducing or health food kind have multiple, but have the medicine of side effect more, and the health food target spot is few, the link shortcoming, need perfect, and cost height, price height.
Summary of the invention: in order to overcome the shortcoming and defect of existing blood fat reducing medicine, the purpose of this invention is to provide a kind of compositions, said composition increases vitamin A, beta-carotene, vitamin B by Herb Gynostemmae Pentaphylli
1, vitamin B
2, vitamin B
6, nicotiamide, pantothenic acid, biotin, vitamin B
12, folic acid, vitamin C, vitamin D, vitamin E and macroelement calcium, magnesium and trace element zinc, selenium, chromium, molybdenum blood fat reducing effect, simultaneously by macroelement calcium, magnesium and trace element zinc, selenium, chromium, molybdenum and vitamin A, beta-carotene, vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid, vitamin C, vitamin D, vitamin E, replenish and strengthen the effect of Herb Gynostemmae Pentaphylli blood fat reducing, even chronic administration is also without any side effect; Because the result of broad research, the inventor have found Herb Gynostemmae Pentaphylli and vitamin A, beta-carotene, vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid, vitamin C, vitamin D vitamin E and macroelement calcium, magnesium and trace element zinc, selenium, chromium, molybdenic novel combination, this novel combination has synergy for blood fat reducing; And singly use Herb Gynostemmae Pentaphylli and vitamin A, beta-carotene, compound vitamin B, vitamin C, vitamin D, vitamin E and macroelement calcium, magnesium and trace element zinc, selenium, chromium, molybdenum, its effect is all not as good as this compositions; There is not incompatibility in this compositions, have no side effect, and cost is low, thereby constitutes the present invention.
The invention provides the pharmaceutical composition that is used for blood fat reducing, it comprises as the Herb Gynostemmae Pentaphylli of active component and vitamin A, beta-carotene, vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid, vitamin C, vitamin D, vitamin E and macroelement calcium, magnesium and trace element zinc, selenium, chromium, molybdenum.
Herb Gynostemmae Pentaphylli is that Cucurbitaceae is overgrow the herb of herbaceous plant Herb Gynostemmae Pentaphylli (GynoStemma pentaphyllum) for many years for using; 14 kinds of the total kinds in the whole world, in state-owned 11 kinds; Ground such as main product is little in peace, Zhejiang, Jiangxi, Fujian, Guangxi; The used Herb Gynostemmae Pentaphylli of the present invention can be with its extract as raw material.
Be used for vitamin B of the present invention
1(VitaminB
1), vitamin B
2(VitaminB
2), nicotiamide (Nicotinamide), pantothenic acid (Pantothenic Acid), biotin (Vitamin H), vitamin B
6(VitaminB
6), vitamin B
12(VitaminB
12), folic acid (Folic Acid), vitamin C (VitaminC), all are water soluble vitamins, do not accumulate in vivo; Vitamin A (Vitamin A), vitamin D (VitaminD), vitamin E (Vitamin E) are fatsoluble vitamiies, and beta-carotene (BetaCarotene) is the precursor substance of vitamin A, and be useful and harmless by the used dosage of the present invention; Zinc (Zn), selenium (Se), chromium (Cr), molybdenum (Mo) are micro elements needed by human, and calcium (Ca), magnesium (Mg) are the macroelements of needed by human; Macroelement calcium among the present invention can be selected calcium gluconate for use, calcium lactate, calcium acetate, calcium caseinate, calcium chloride, calcium citrate, calcium malate, calcium cirate malate, calcium hydrogen phosphate, dalcium biphosphate, calcium phosphate, calcium sulfate, calcium ascorbate, calcium glycerophosphate, calcium carbonate etc., macroelement magnesium can be selected magnesium chloride for use, magnesium gluconate, magnesium lactate, magnesium citrate, magnesium hydrogen phosphate, magnesium phosphate, magnesium glycerophosphate, magnesium carbonate etc., trace element zinc can be selected zinc citrate for use, zinc acetate, zinc carbonate, zinc oxide, zinc chloride, zinc lactate, zinc sulfate, zinc gluconate, single zinc methionine etc., trace element-selenium can be selected Selenomethionine for use, methoxybenzyl cyanic acid selenium, the two cyanic acid selenium of phenylene, sodium selenite, selenocarrageenan, selenocysteine, the selenizing methionine, sodium selenate etc., trace element chromium can be selected chromium trichloride for use, nicotinic acid chromium, chromium picolinate, trivalent chromiums such as chromium yeast, trace element molybdenum can be selected ammonium molybdate for use, sodium molybdate etc. all have professional production factory and supplier.
Compositions of the present invention mainly is applicable to people with hyperlipidemia, and by the present invention, the effective dose of Herb Gynostemmae Pentaphylli is counted 500-15000mg/ days with whole crude drug, vitamin B
1Effective dose be 0.5-20mg/ days, vitamin B
2Effective dose be 0.5-20mg/ days, the effective dose of nicotiamide is 5-50mg/ days, the effective dose of pantothenic acid is 2-20mg/ days, the effective dose of biotin is 0.01-0.1mg/ days, vitamin B
6Effective dose be 0.5-10mg/ days, vitamin B
12Effective dose be 0.001-0.025mg/ days, the effective dose of folic acid is 0.1-1mg/ days, ascorbic effective dose is 30-500mg/ days, the effective dose of vitamin A and/or beta-carotene (in retinol equivalent) is 250-800 μ gRE/ days; The effective dose of vitamin D is 0.0015-0.01mg/ days, the effective dose of vitamin E (in the alpha-tocopherol equivalent) is 5-150mg α-TE/ days, the effective dose of macroelement calcium is counted 250-1000mg/ days with element calcium, the effective dose of magnesium is counted 100-300mg/ days with element magnesium, the effective dose of trace element zinc is counted 5-20mg/ days with element zinc, selenic effective dose is counted 0.015-0.1mg/ days with elemental selenium, the effective dose of chromium is counted 0.015-0.15mg/ days with elemental chromium, and molybdenic effective dose is counted 0.02-0.06mg/ days with molybdenum.
Compositions of the present invention can or directly be taken by following pharmaceutical dosage forms dispenser, for example, oral formulations is (as granule, powder, capsule, ball, sheet, dry syrup, liquid formulation), or food such as food (as cookies), mix and prepare with other known additives, this class additive is for example: carrier, disintegrating agent, slow releasing agent, excipient, filler, covering, binding agent, lubricant, antioxidant, apply agent, coloring agent, correctives, sweeting agent, sucrose succedaneum, nutrition enhancer, flavouring agent, surfactant, plasticizer, the PH regulator, freshener, suspending agent, defoamer, antiseptic, thickening agent, solubilisation aids etc. are prepared or they are added food as functional component or additive by usual way.
By the present invention, Herb Gynostemmae Pentaphylli, vitamin A, beta-carotene, vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid, vitamin C, vitamin D, vitamin E and macroelement calcium, magnesium and trace element zinc, selenium, chromium, molybdenum each component can distinguish preparation, the preparation of each component can be mixed the back when using and use or do not mix simultaneously and use.
Advantage of the present invention be this compositions from too many levels, multisystem, many target spots blood fat reducing, the effect of collaborative performance effect is arranged between the each component, blood fat reducing is had significant effect, sufficient raw, cost is low, and each component has no side effect in the compositions, no incompatibility.
Subordinate list 1 causes diabetes model rat blood fat reducing test effect relatively for this compositions and Herb Gynostemmae Pentaphylli component and vitamin added elements component to (STZ).
Relatively tabulate below with reference to embodiment and test implementation example effect and to be described in detail the present invention.
Embodiment 1:
Herb Gynostemmae Pentaphylli 800mg,
Vitamin B
13mg,
Vitamin B
23mg,
Vitamin B
62mg,
Nicotiamide 10mg,
Vitamin C 30mg,
Zinc lactate (in trace element zinc) 10mg,
Sodium selenate (in trace element-selenium) 0.02mg,
Chromium picolinate (in trace element chromium) 0.01mg,
Molybdic acid is received (in trace element molybdenum) 0.03mg,
Magnesium lactate (in element magnesium) 200mg,
Vitamin E (in the alpha-tocopherol equivalent) 10mg α-TE.
Said components is further mixed equably with the additive of appropriate amount such as aluminosilicate magnesium, poly-solvate 60 and propylene glycol, the gained mixture is inserted capsule equably and 9 capsules, every day 3 times, each 3 capsules.
Embodiment 2:
Herb Gynostemmae Pentaphylli 1500mg,
Vitamin B
13mg,
Vitamin B
23mg,
Vitamin B
62mg,
Nicotiamide 10mg,
Vitamin C 100mg,
Zinc lactate (in trace element zinc) 8mg,
Sodium selenate (in trace element-selenium) 0.02mg,
Chromium yeast (in trace element chromium) 0.02mg,
Molybdic acid is received (in trace element molybdenum) 0.04mg,
Calcium lactate (in element calcium) 600mg,
Magnesium lactate (in element magnesium) 200mg,
Vitamin D 0.002mg,
Vitamin E (in the alpha-tocopherol equivalent) 10mg α-TE.
Said components is further mixed equably with the additive of appropriate amount such as aluminosilicate magnesium, poly-solvate 60 and propylene glycol, the gained mixture is inserted capsule equably and 9 capsules, every day 3 times, each 3 capsules.
Embodiment 3:
Herb Gynostemmae Pentaphylli 2500mg,
Vitamin B
13mg,
Vitamin B
23mg,
Vitamin B
62mg,
Folic acid 0.3mg,
Vitamin B
120.003mg,
Nicotiamide 10mg,
Vitamin C 30mg,
Zinc lactate (in trace element zinc) 10mg,
Sodium selenate (in trace element-selenium) 0.02mg,
Chromium yeast (in trace element chromium) 0.02mg,
Sodium molybdate (in trace element molybdenum) 0.03mg,
Calcium lactate (in element calcium) 600mg,
Magnesium lactate (in element magnesium) 200mg,
Vitamin D 0.002mg,
Vitamin E (in the alpha-tocopherol equivalent) 10mg α-TE.
Said components is further mixed equably with the additive of appropriate amount such as aluminosilicate magnesium, poly-solvate 60 and propylene glycol, the gained mixture is inserted capsule equably and 9 capsules, every day 3 times, each 3 capsules.
Embodiment 4:
Herb Gynostemmae Pentaphylli 4000mg,
Vitamin B
13mg,
Vitamin B
23mg,
Vitamin B
62mg,
Folic acid 0.3mg,
Vitamin B
120.003mg,
Nicotiamide 10mg,
Biotin 0.08mg,
Vitamin C 30mg,
Zinc lactate (in trace element zinc) 10mg,
Sodium selenate (in trace element-selenium) 0.02mg,
Chromium yeast (in trace element chromium) 0.02mg,
Sodium molybdate (in trace element molybdenum) 0.03mg,
Calcium lactate (in element calcium) 600mg,
Magnesium lactate (in element magnesium) 200mg,
Vitamin D 0.002mg,
Vitamin E (in the alpha-tocopherol equivalent) 10mg α-TE.
Above-mentioned component is further mixed equably with additive such as mannitol, hydroxypropyl cellulose, aluminosilicate magnesium and the flavoring agent of appropriate amount, again the gained mixture is made 3 bag shot-like particles; Obey every day 3 times, obey a bag at every turn.
Embodiment 5:
Herb Gynostemmae Pentaphylli 5000mg,
Vitamin B
13mg,
Vitamin B
23mg,
Vitamin B
62mg,
Folic acid 0.3mg,
Vitamin B
120.003mg,
Nicotiamide 10mg,
Pantothenic acid 5mg,
Biotin 0.06mg,
Vitamin C 30mg,
Zinc lactate (in trace element zinc) 10mg,
Sodium selenate (in trace element-selenium) 0.02mg,
Chromium yeast (in trace element chromium) 0.02mg,
Sodium molybdate (in trace element molybdenum) 0.03mg,
Calcium lactate (in element calcium) 600mg,
Magnesium lactate (in element magnesium) 200mg,
Vitamin D 0.002mg,
Vitamin E (in the alpha-tocopherol equivalent) 10mg α-TE.
Above-mentioned component is further mixed equably with additive such as mannitol, hydroxypropyl cellulose, aluminosilicate magnesium and the flavoring agent of appropriate amount, again the gained mixture is made 3 bag shot-like particles; Obey every day 3 times, obey a bag at every turn.
Embodiment 6:
Herb Gynostemmae Pentaphylli 500mg,
Vitamin B
10.5mg,
Vitamin B
20.5mg,
Vitamin B
60.5mg,
Folic acid 0.1mg,
Vitamin B
120.001mg,
Nicotiamide 5mg,
Pantothenic acid 2mg,
Biotin 0.01mg,
Vitamin C 30mg,
Zinc lactate (in trace element zinc) 5mg,
Sodium selenate (in trace element-selenium) 0.015mg,
Chromium yeast (in trace element chromium) 0.015mg,
Sodium molybdate (in trace element molybdenum) 0.02mg,
Calcium lactate (in element calcium) 250mg,
Magnesium lactate (in element magnesium) 100mg,
Retinol equivalent (vitamin A and/or beta-carotene) 200 μ g RE,
Vitamin D 0.015mg,
Vitamin E (in the alpha-tocopherol equivalent) 5mg α-TE.
Above-mentioned component is further mixed equably with additive such as mannitol, hydroxypropyl cellulose, aluminosilicate magnesium and the flavoring agent of appropriate amount, again the gained mixture is made 3 bag shot-like particles; Obey every day 3 times, obey a bag at every turn.
Embodiment 7:
Herb Gynostemmae Pentaphylli 15000mg,
Vitamin B
120mg,
Vitamin B
220mg,
Vitamin B
610mg,
Folic acid 1mg,
Vitamin B
120.025mg,
Nicotiamide 50mg,
Pantothenic acid 20mg,
Biotin 0.1mg,
Vitamin C 500mg,
Zinc lactate (in trace element zinc) 20mg,
Sodium selenate (in trace element-selenium) 0.1mg,
Chromium yeast (in trace element chromium) 0.15mg,
Sodium molybdate (in trace element molybdenum) 0.06mg,
Calcium lactate (in element calcium) 1000mg,
Magnesium lactate (in element magnesium) 300mg,
Retinol equivalent (vitamin A and/or beta-carotene) 800 μ g RE,
Vitamin D 0.01mg,
Vitamin E (in the alpha-tocopherol equivalent) 150mg α-TE.
Above-mentioned component is further mixed equably with additive such as mannitol, hydroxypropyl cellulose, aluminosilicate magnesium and the flavoring agent of appropriate amount, again the gained mixture is made 3 bag shot-like particles; Obey every day 3 times, obey a bag at every turn, serve on 7, withdrew 3, obeyed again 7.
Confirm that through animal experiment this compositions belongs to nontoxic level; The crowd takes and does not also see toxicity.
Embodiment 8: this compositions causes diabetes model rat blood fat reducing test effect relatively with each component to (STZ).
Selecting SD is 48 feeds of male rat high lipid food, press an intraperitoneal injection STZ of 25mg/kg body weight (streptozotocin) after raising for 4 weeks, fasting is after 8 hours after 2 weeks, gavage the 20%D-glucose solution by the 2g/kg body weight, do the oral glucose tolerance test, all 0 and 2 hour blood glucose is respectively greater than 7.0 and the rat of 11.0mmol/L, as diabetes modeling success rat.Modeling success rat is divided into 4 groups at random, 12 every group, is respectively matched group (A group), the B group, C group, D group, test is respectively organized distilled water suspension oral gavage that every day, per os gave checking matter and equivalent once, matched group gives equivalent normal saline filling stomach once every day, in administration 12 week back fasting on the 3rd 10 hours, carotid artery blood sampling, measure T-CHOL respectively, triglyceride, high density lipoprotein, three indexs.
Related data sees attached list 1.
Subordinate list 1: this compositions causes diabetes model rat blood fat reducing test effect relatively with Herb Gynostemmae Pentaphylli component and vitamin added elements component to (STZ):
From table 1, can obviously find out, take this composite preparation and take Herb Gynostemmae Pentaphylli component and vitamin added elements component contrast high blood lipid model rat blood fat reducing test effect the difference of highly significant is arranged.
Claims (6)
1, a kind of pharmaceutical composition that is used for blood fat reducing is characterized in that it is made by weight ratio by following raw materials according:
Herb Gynostemmae Pentaphylli 500-15000mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Vitamin B
60.5-10mg,
Folic acid 0-1mg,
Vitamin B
120-0.025mg,
Nicotiamide 5-50mg,
Pantothenic acid 0-20mg,
Biotin 0-0.1mg,
Vitamin C 30-500mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Chromium 0.015-0.15mg,
Molybdenum 0.02-0.06mg,
Calcium 0-1000mg,
Magnesium 100-300mg,
Retinol equivalent [vitamin A and/or beta-carotene] 0-800 μ gRE,
Vitamin D 0-0.01mg,
Vitamin E 5-150mg a-TE.
2, the pharmaceutical composition that is used for blood fat reducing according to claim 1 is characterized in that it is made by weight ratio by following raw materials according:
Herb Gynostemmae Pentaphylli 500-15000mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Vitamin B
60.5-10mg,
Folic acid 0-10mg,
Vitamin B
120-0.025mg,
Nicotiamide 5-50mg,
Pantothenic acid 0-20mg,
Biotin 0-0.1mg,
Vitamin C 30-500mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Chromium 0.015-0.15mg,
Molybdenum 0.02-0.06mg,
Calcium 250-1000mg,
Magnesium 100-300mg,
Retinol equivalent [vitamin A and/or beta-carotene] 0-800 μ gRE,
Vitamin D 0.0015-0.01mg,
Vitamin E 5-150mg a-TE.
3, the pharmaceutical composition that is used for blood fat reducing according to claim 1 is characterized in that it is made by weight ratio by following raw materials according:
Herb Gynostemmae Pentaphylli 500-15000mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Vitamin B
60.5-10mg,
Folic acid 0.1-1mg,
Vitamin B
120.001-0.025mg,
Nicotiamide 5-50mg,
Pantothenic acid 0-20mg,
Biotin 0-0.1mg,
Vitamin C 30-500mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Chromium 0.015-0.15mg,
Molybdenum 0.02-0.06mg,
Calcium 250-1000mg,
Magnesium 100-300mg,
Retinol equivalent [vitamin A/or beta-carotene] 0-800 μ gRE,
Vitamin D 0.0015-0.01mg,
Vitamin E 5-150mg a-TE.
4, the pharmaceutical composition that is used for blood fat reducing according to claim 1 is characterized in that it is made by weight ratio by following raw materials according:
Herb Gynostemmae Pentaphylli 500-15000mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Vitamin B
60.5-10mg,
Folic acid 0.1-1mg,
Vitamin B
120.001-0.025mg,
Nicotiamide 5-50mg,
Pantothenic acid 0-20mg,
Biotin 0.01-0.1mg,
Vitamin C 30-500mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Chromium 0.015-0.15mg,
Molybdenum 0.02-0.06mg,
Calcium 250-1000mg,
Magnesium 100-300mg,
Retinol equivalent [vitamin A and/or beta-carotene] 0-800 μ gRE,
Vitamin D 0.0015-0.01mg,
Vitamin E 5-150mg a-TE.
5, the pharmaceutical composition that is used for blood fat reducing according to claim 1 is characterized in that it is made by weight ratio by following raw materials according:
Herb Gynostemmae Pentaphylli 500-15000mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Vitamin B
60.5-10mg,
Folic acid 0.1-1mg,
Vitamin B
120.001-0.025mg,
Nicotiamide 5-50mg,
Pantothenic acid 2-20mg,
Biotin 0.01-0.1mg,
Vitamin C 30-500mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Chromium 0.015-0.15mg,
Molybdenum 0.02-0.06mg,
Calcium 250-1000mg,
Magnesium 100-300mg,
Retinol equivalent [vitamin A and/or beta-carotene] 0-800 μ gRE,
Vitamin D 0.0015-0.01mg,
Vitamin E 5-150mg a-TE.
6, the pharmaceutical composition that is used for blood fat reducing according to claim 1 is characterized in that it is made by weight ratio by following raw materials according:
Herb Gynostemmae Pentaphylli 500-15000mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Vitamin B
60.5-10mg,
Folic acid 0.1-1mg,
Vitamin B
120.001-0.025mg,
Nicotiamide 5-50mg,
Pantothenic acid 2-20mg,
Biotin 0.01-0.1mg,
Vitamin C 30-500mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Chromium 0.015-0.15mg,
Molybdenum 0.02-0.06mg,
Calcium 250-1000mg,
Magnesium 100-300mg,
Retinol equivalent [vitamin A and/or beta-carotene] 250-800 μ gRE,
Vitamin D 0.0015-0.01mg,
Vitamin E 5-150mg a-TE.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009100804986A CN101584732A (en) | 2009-03-19 | 2009-03-19 | The pharmaceutical composition that is used for blood fat reducing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009100804986A CN101584732A (en) | 2009-03-19 | 2009-03-19 | The pharmaceutical composition that is used for blood fat reducing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101584732A true CN101584732A (en) | 2009-11-25 |
Family
ID=41369301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2009100804986A Pending CN101584732A (en) | 2009-03-19 | 2009-03-19 | The pharmaceutical composition that is used for blood fat reducing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101584732A (en) |
-
2009
- 2009-03-19 CN CNA2009100804986A patent/CN101584732A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101474304A (en) | Pharmaceutical composition for reducing blood sugar and blood fat | |
| CN101574370A (en) | Drug composition for reducing blood sugar and blood fat | |
| CN101584706A (en) | Pharmaceutical composition used for reducing blood sugar and blood fat and treating diabetes | |
| CN101596276A (en) | The pharmaceutical composition that is used for blood sugar lowering and blood fat and treatment diabetes | |
| CN101584732A (en) | The pharmaceutical composition that is used for blood fat reducing | |
| CN101596281A (en) | The pharmaceutical composition that is used for blood sugar lowering and blood fat | |
| CN101579463A (en) | Medicine composition for reducing blood sugar and blood fat, and curing diabetes | |
| CN101574365A (en) | Drug composition for reducing blood sugar and blood fat | |
| CN101574404A (en) | Drug composition for reducing blood fat | |
| CN101596284A (en) | The pharmaceutical composition that is used for blood sugar lowering and blood fat | |
| CN101461868A (en) | Pharmaceutical composition for reducing blood sugar, blood fat and treating diabetes | |
| CN101584731A (en) | The pharmaceutical composition that is used for blood fat reducing | |
| CN101601683A (en) | The pharmaceutical composition that is used for blood sugar lowering and blood fat and treatment diabetes | |
| CN101632790A (en) | Drug combination for reducing blood sugar level | |
| CN101632702A (en) | Drug combination for reducing blood lipid level | |
| CN101632703A (en) | Drug combination for reducing blood lipid level | |
| CN101669976A (en) | Pharmaceutical composition for reducing blood lipids | |
| CN101574402A (en) | Drug composition for reducing blood fat | |
| CN101632698A (en) | Drug combination for reducing blood lipid level | |
| CN101569651A (en) | Medicinal composition for lowering blood sugar | |
| CN101632701A (en) | Drug combination for reducing blood lipid level | |
| CN101632700A (en) | Drug combination for reducing blood lipid level | |
| CN101569637A (en) | Medicinal composition for lowering blood fat | |
| CN101590150A (en) | The pharmaceutical composition that is used for blood sugar lowering and blood fat | |
| CN101596212A (en) | The pharmaceutical composition that is used for blood sugar lowering and blood fat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20091125 |